BofA analyst Alec Stranahan lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $41 from $44 and keeps a Buy rating on the shares. While the firm notes Agios plans to file for accelerated approval and has already submitted a confirmatory trial proposal with a new primary endpoint, it says the topline HIBISCUS data from Novo Nordisk’s (NVO) etavopivat in sickle cell disease may increase the regulatory risk for Agios’ mitapivat.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Maintaining Buy on Agios: Mitapivat’s Risk-Adjusted Upside Despite Etavopivat Competition and Regulatory Uncertainty
- Agios Pharmaceuticals: Mitapivat’s Early-Mover Advantage and Diversified Pipeline Support Buy Rating Despite Emerging Sickle Cell Competition
- H.C. Wainwright cuts Agios target on smaller market post Novo data
- Agios Pharmaceuticals falls -23.4%
- Midday Fly By: QXO to acquire TopBuild, Lilly to buy Kelonia